comparemela.com

Page 12 - Disease Specific Epitopes News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ProMIS Neurosciences Appoints Internationally Recognized Neuroscientist Dr Cheryl Wellington to its Scientific Advisory Board

27.01.2022 - TORONTO, Ontario and CAMBRIDGE, Mass., Jan. 27, 2022 (GLOBE NEWSWIRE) - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins .

New zealand generalNew zealandUnited kingdomUnited statesNicholas rigopulosNeil cashmanToronto stock exchangePromis neurosciences incChief scientificNorth americaScientific advisory boardCollective coordinatesDisease specific epitopesInvestor relations

ProMIS Neurosciences to Participate in the Biotech Showcase 2022 Virtual Panel Discussion: Aduhelm Stimulating the Next Generation of Alzheimer s Treatment

07.01.2022 - TORONTO, Ontario and CAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins .

United kingdomUnited statesMichael mcfaddenBrent vaughanLisa ricciardiTravis bondEugene williamsPhyllis barkman ferrellNicholas rigopulosEli lilly companyPromis neurosciences incAltoida incToronto stock exchangeCognition therapeutics incAlpha cognition incGlobal head

ProMIS Neurosciences Inc : ProMIS Neurosciences Announces Update to Senior Management Team

Expanded management team to lead development programs with special focus on PMN310 for Alzheimer's diseaseTORONTO and CAMBRIDGE, Mass., Oct. 22, 2021 (GLOBE NEWSWIRE) ProMIS Neurosciences, Inc. (TSX:

United statesSan diegoUnited kingdomElliot goldsteinGavint malenfantDennis chenEugene williamsNicholas rigopulosMichael grundmanErnestd bushUniversity of californiaBiopharmaceutical developmentCentral nervous system advisory committeePromis neurosciences incRegulatory affairsAlzheimer disease cooperative study

ProMIS Neurosciences Inc : ProMIS Neurosciences Appoints Accomplished Biotech Executive, Dr Maggie Shafmaster, to its Board of Directors

TORONTO and CAMBRIDGE, Mass., Oct. 22, 2021 (GLOBE NEWSWIRE) ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics

New yorkUnited statesUnited kingdomSanofi pasteurEugene williamsMaggie shafmasterNicholas rigopulosYork law schoolToronto stock exchangeCornell university graduate school of medical sciencesPromis neurosciences incExecutive chairmanMolecular biologyCornell university graduate schoolMedical sciencesNew york law

ProMIS Neurosciences Inc : ProMIS Neurosciences Files Special Meeting Proxy Material

For any questions, please contact ProMIS' proxy solicitation agent, Laurel Hill Advisory Group at 1-877-452-7184. TORONTO and CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) ProMIS Neurosciences

Laurel hillUnited statesUnited kingdomEugene williamsNicholas rigopulosCompany commonToronto stock exchangePromis neurosciences incUnited states stock exchange listingLaurel hill advisory groupCommon shares of the companySpecial meetingCommon sharesCommon shareExecutive chairmanAmerica toll free

vimarsana © 2020. All Rights Reserved.